Literature DB >> 10682305

Effect of sodium benzoate in the treatment of atypical nonketotic hyperglycinaemia.

J M Neuberger1, S Schweitzer, M O Rolland, R Burghard.   

Abstract

A 6-month-old girl presented with hypotonia and mild psychomotor retardation. Subsequently, an atypical manifestation of a nonketotic hyperglycinaemia was diagnosed, confirmed by significantly reduced activity of the glycine cleavage system in the liver tissue. After the patient developed hypsarrhythmia and had a single cerebral seizure, treatment with both sodium benzoate and dextromethorphan was started. During the following year, the girl was free of seizures with improvement of the EEG activity and showed retarded but continuously progressing psychomotor development. At the age of 20 months she began to walk freely but had generalized muscular hypotonia and moderate mental retardation. Discontinuation of dextromethorphan medication after one year of treatment did not change the clinical and electroencephalographic status. However, after cessation of sodium benzoate therapy, epileptic activity in the EEG and behavioural changes occurred. These changes disappeared promptly after sodium benzoate therapy was reinstituted. Thus, this case of mild atypical nonketotic hyperglycinaemia with only moderate psychomotor retardation and without epilepsy benefited from treatment with sodium benzoate in terms of electroencephalographic and behavioural changes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682305     DOI: 10.1023/a:1005642728513

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  14 in total

1.  Efficacy of low-dose dextromethorphan in the treatment of nonketotic hyperglycinemia.

Authors:  R Alemzadeh; K Gammeltoft; K Matteson
Journal:  Pediatrics       Date:  1996-06       Impact factor: 7.124

2.  Nonketotic hyperglycinemia: studies in an atypical variant.

Authors:  H S Singer; D Valle; K Hayasaka; K Tada
Journal:  Neurology       Date:  1989-02       Impact factor: 9.910

3.  Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia.

Authors:  A Boneh; Y Degani; M Harari
Journal:  Pediatr Neurol       Date:  1996-09       Impact factor: 3.372

4.  Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia.

Authors:  B A Barshop; J Breuer; J Holm; J Leslie; W L Nyhan
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine.

Authors:  M Benveniste; M L Mayer
Journal:  Biophys J       Date:  1991-03       Impact factor: 4.033

6.  Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant.

Authors:  A Hamosh; J W McDonald; D Valle; C A Francomano; E Niedermeyer; M V Johnston
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

7.  Nonketotic hyperglycinemia: clinical and electrophysiologic effects of dextromethorphan, an antagonist of the NMDA receptor.

Authors:  B Schmitt; B Steinmann; R Gitzelmann; L Thun-Hohenstein; H Mascher; G Dumermuth
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

8.  Nonketotic hyperglycinemia in two retarded adults: a mild form of infantile nonketotic hyperglycinemia.

Authors:  D B Flannery; J Pellock; D Bousounis; P Hunt; C Nance; B Wolf
Journal:  Neurology       Date:  1983-08       Impact factor: 9.910

9.  Nonketotic hyperglycinemia: analyses of glycine cleavage system in typical and atypical cases.

Authors:  K Hayasaka; K Tada; N Fueki; Y Nakamura; W L Nyhan; K Schmidt; S Packman; M R Seashore; E Haan; D M Danks
Journal:  J Pediatr       Date:  1987-06       Impact factor: 4.406

10.  The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia.

Authors:  J A Wolff; S Kulovich; A L Yu; C N Qiao; W L Nyhan
Journal:  Am J Dis Child       Date:  1986-06
View more
  4 in total

1.  The effect of hyperglycinemic treatment in captive-bred Vervet monkeys (Chlorocebus aethiops).

Authors:  Zandisiwe E Magwebu; Mikateko Mazinu; Sahar Abdul-Rasool; Chesa G Chauke
Journal:  Metab Brain Dis       Date:  2019-06-22       Impact factor: 3.584

2.  Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF.

Authors:  Dhruv Patel; Arundhati Jana; Avik Roy; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-22       Impact factor: 4.147

Review 3.  Nonketotic Hyperglycinemia: Insight into Current Therapies.

Authors:  Magdalena Nowak; Piotr Chuchra; Justyna Paprocka
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

4.  Reduction of Lewy Body Pathology by Oral Cinnamon.

Authors:  Sumita Raha; Debashis Dutta; Avik Roy; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-05       Impact factor: 7.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.